Published in J Immunol on September 15, 1998
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol (2012) 1.71
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest (2004) 1.70
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res (2012) 1.67
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A (2002) 1.20
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res (2015) 1.17
A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity. Protein Sci (1999) 1.15
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
CD19-CAR trials. Cancer J (2014) 1.09
Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation. Immunology (2006) 1.07
Engineering T cells for cancer therapy. Br J Cancer (2005) 1.05
Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res (2008) 1.03
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther (2011) 1.00
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol (2013) 0.98
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res (2016) 0.95
Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev (2016) 0.95
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem (2010) 0.95
Engineered T cells for cancer therapy. Cancer Immunol Immunother (2014) 0.95
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
Lymphocyte display: a novel antibody selection platform based on T cell activation. PLoS One (2009) 0.88
CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. Clin Exp Immunol (2006) 0.88
Modular extracellular sensor architecture for engineering mammalian cell-based devices. ACS Synth Biol (2014) 0.86
CAR-T Cell Therapy for Lymphoma. Annu Rev Med (2015) 0.86
Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol (2012) 0.85
Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech (2015) 0.85
Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther (2009) 0.85
Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel) (2014) 0.84
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Genetically engineered T cells for the treatment of cancer. J Intern Med (2013) 0.83
T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res (2014) 0.83
Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther (2015) 0.82
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol (2015) 0.82
CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics (2016) 0.81
Chimeric antigen receptor-redirected T cells return to the bench. Semin Immunol (2016) 0.81
Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer (2004) 0.80
A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One (2014) 0.79
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) (2012) 0.79
From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells. Hum Gene Ther (2014) 0.79
Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol (2011) 0.79
Adoptive immunotherapy of cancer: Gene transfer of T cell specificity. Self Nonself (2011) 0.78
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol (2016) 0.78
Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol (2008) 0.78
An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. PLoS One (2016) 0.77
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther (2015) 0.77
CARs in chronic lymphocytic leukemia -- ready to drive. Curr Hematol Malig Rep (2013) 0.77
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest (2017) 0.76
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood (2016) 0.76
Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy. Transl Res (2017) 0.76
From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. Semin Oncol (2014) 0.75
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer (2015) 0.75
New approaches for the immunotherapy of acute myeloid leukemia. Discov Med (2015) 0.75
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist (2016) 0.75
Recombination-deletion between homologous cassettes in retrovirus is suppressed via a strategy of degenerate codon substitution. Mol Ther Methods Clin Dev (2014) 0.75
Engineering cell-based therapies to interface robustly with host physiology. Adv Drug Deliv Rev (2016) 0.75
A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75
The other face of chimeric antigen receptors. Mol Ther (2014) 0.75
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. Cancer Gene Ther (2017) 0.75
Engineering Chimeric Antigen Receptors. Acta Naturae (2017) 0.75
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer (2017) 0.75
Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol (2017) 0.75
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Front Immunol (2017) 0.75
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annu Rev Immunol (2017) 0.75
Most Do, but Some Do Not: CD4⁺CD25(-) T Cells, but Not CD4⁺CD25⁺ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR). Cancers (Basel) (2017) 0.75
High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (N Y) (1990) 1.92
Distinct intracellular localization of Lck and Fyn protein tyrosine kinases in human T lymphocytes. J Cell Biol (1994) 1.58
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol (1993) 1.50
Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res (1994) 1.24
Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. Hum Antibodies Hybridomas (1993) 1.06
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer (1995) 1.04
Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma. Br J Obstet Gynaecol (1997) 1.01
Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix (1990) 0.99
Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem (2001) 0.99
The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines. Nucleic Acids Res (1991) 0.97
Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng (1994) 0.95
Expression, purification and characterization of B72.3 Fv fragments. Biochem J (1993) 0.83
Uterine arteriovenous malformation: fertility-sparing surgery using unilateral ligation of uterine artery and ovarian ligament. Int J Gynecol Cancer (2007) 0.82
Selecting and designing cell lines for improved physiological characteristics. Cytotechnology (1994) 0.81
Amplification using CHO cell expression vectors. Curr Protoc Mol Biol (2002) 0.79
Antagonism of the hypnotic effect of midazolam in children: a randomized, double-blind study of placebo and flumazenil administered after midazolam-induced anaesthesia. Br J Anaesth (1991) 0.78
In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes. Int Immunopharmacol (2008) 0.78
Macrophages induce antibody-dependent cytostasis but not lysis in guinea pig leukaemic cells. Br J Cancer (1983) 0.77
Purification of recombinant chimeric B72.3 Fab' and F(ab')2 using streptococcal protein G. Protein Expr Purif (1992) 0.77
Minimising cardiac anaesthetic risk: the tortoise or the hare? Anaesthesia (1996) 0.75
Response to: Increasing use of DNR orders in the elderly worldwide: whose choice is it. J Med Ethics (2003) 0.75
Monoclonal antibodies recognizing cell surface antigens in Drosophila melanogaster. Dev Biol (1982) 0.75
The pharmacokinetics of selenium in psoriasis and atopic dermatitis. Acta Derm Venereol (1988) 0.75
An evaluation of prolonged oximetric data acquisition. Anaesth Intensive Care (1992) 0.75
Monoclonal antibodies for purification and assay of IL-2. Lymphokine Res (1986) 0.75
Convulsions following bupivacaine infiltration for excision of carotid body tumour. Anaesth Intensive Care (1993) 0.75
Comparative pharmacokinetics of propofol in Chinese adults and children. Methods Find Exp Clin Pharmacol (1992) 0.75
Medullary sponge kidney and urolithiasis. Clin Radiol (1982) 0.75
The secretion of active recombinant human gastric lipase by Saccharomyces cerevisiae. Protein Expr Purif (1996) 0.75
Humanization of an anti-mucin antibody for breast and ovarian cancer therapy. Adv Exp Med Biol (1994) 0.75